====== Studienlage ======
Die folgenden Studien können als Argumentation für eine Wirksamkeit der Off-Label-Behandlung genutzt werden

==== Low Dose Naltrexon (LDN) ====

  * [[https://doi.org/10.1016/j.bbih.2022.100485|Safe efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.]]
  * [[https://doi.org/10.1016/j.bbih.2024.100733|Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19]]
  * [[https://doi.org/10.1080/21641846.2019.1692770|Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)]]
  * [[https://doi.org/10.1016/j.clinthera.2023.12.009|Low-dose Naltrexone Improves post–COVID-19 condition Symptoms]]
  * [[https://pubmed.ncbi.nlm.nih.gov/40458265/|Low-Dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients]]
==== Amifampridin ====
  * [[https://www.cureus.com/articles/218002-reduced-fatigue-symptoms-in-the-post-covid-syndrome-with-amifampridine-a-collective-casuistry-with-double-blind-discontinuation-trials#!/|Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials]]

==== Low Dose Aripiprazol (LDA) ===
  * [[https://pubmed.ncbi.nlm.nih.gov/33536023/|Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole]]